NO20051469L - Immunstimulerende nukleinsyrer. - Google Patents

Immunstimulerende nukleinsyrer.

Info

Publication number: NO20051469L
Authority: NO; Norway
Prior art keywords: immune; nucleic acids; stimulating nucleic; stimulating; soft
Prior art date: 2002-08-19

Application number

NO20051469A

Other languages

English (en)

Norwegian (no)

Inventor

Eugen Uhlmann

Arthur M Krieg

Ulrike Samulowitz

Jorg Vollmer

Marion Jurk

Grayson Lipford

Robert Rankin

Original Assignee

Coley Pharm Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-08-19

Filing date

2005-03-18

Publication date

2005-05-19

2005-03-18 Application filed by Coley Pharm Gmbh filed Critical Coley Pharm Gmbh

2005-05-19 Publication of NO20051469L publication Critical patent/NO20051469L/no

Links

150000007523 nucleic acids Chemical class 0.000 title 1
102000039446 nucleic acids Human genes 0.000 title 1
108020004707 nucleic acids Proteins 0.000 title 1
108091034117 Oligonucleotide Proteins 0.000 abstract 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
230000028993 immune response Effects 0.000 abstract 1
230000003308 immunostimulating effect Effects 0.000 abstract 1
230000004936 stimulating effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/312—Phosphonates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/312—Phosphonates
- C12N2310/3125—Methylphosphonates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/313—Phosphorodithioates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/336—Modified G
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Zoology (AREA)
Pulmonology (AREA)
Epidemiology (AREA)
Physics & Mathematics (AREA)
Biophysics (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Transplantation (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Saccharide Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)

NO20051469A 2002-08-19 2005-03-18 Immunstimulerende nukleinsyrer. NO20051469L (no)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US40482002P	2002-08-19	2002-08-19
US40447902P	2002-08-19	2002-08-19
US42970102P	2002-11-27	2002-11-27
US44737703P	2003-02-14	2003-02-14
PCT/US2003/025935 WO2004016805A2 (fr)	2002-08-19	2003-08-19	Acides nucléiques immunostimulants

Publications (1)

Publication Number	Publication Date
NO20051469L true NO20051469L (no)	2005-05-19

Family

ID=31892263

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20051469A NO20051469L (no)	2002-08-19	2005-03-18	Immunstimulerende nukleinsyrer.

Country Status (27)

Country	Link
US (2)	US8283328B2 (fr)
EP (2)	EP2290078B1 (fr)
JP (2)	JP5414961B2 (fr)
KR (2)	KR20080011247A (fr)
AR (1)	AR040996A1 (fr)
AU (2)	AU2003259916B2 (fr)
BR (1)	BR0313414A (fr)
CA (1)	CA2493753C (fr)
DK (2)	DK1538904T3 (fr)
EC (1)	ECSP055687A (fr)
ES (2)	ES2634328T3 (fr)
HU (2)	HUE030347T2 (fr)
IL (1)	IL166376A (fr)
MA (1)	MA27468A1 (fr)
MX (1)	MXPA05002014A (fr)
NO (1)	NO20051469L (fr)
NZ (2)	NZ560722A (fr)
OA (1)	OA12906A (fr)
PE (2)	PE20040900A1 (fr)
PL (2)	PL232260B1 (fr)
PT (2)	PT2290078T (fr)
RS (1)	RS20050126A (fr)
SI (1)	SI2290078T1 (fr)
SV (1)	SV2008001602A (fr)
TW (1)	TW200412981A (fr)
UY (1)	UY27945A1 (fr)
WO (1)	WO2004016805A2 (fr)

Families Citing this family (125)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6727230B1 (en) *	1994-03-25	2004-04-27	Coley Pharmaceutical Group, Inc.	Immune stimulation by phosphorothioate oligonucleotide analogs
US6239116B1 (en) *	1994-07-15	2001-05-29	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US6429199B1 (en) *	1994-07-15	2002-08-06	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules for activating dendritic cells
US6207646B1 (en)	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US20030026782A1 (en) *	1995-02-07	2003-02-06	Arthur M. Krieg	Immunomodulatory oligonucleotides
US7935675B1 (en) *	1994-07-15	2011-05-03	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US5981501A (en) *	1995-06-07	1999-11-09	Inex Pharmaceuticals Corp.	Methods for encapsulating plasmids in lipid bilayers
EP0855184A1 (fr) *	1997-01-23	1998-07-29	Grayson B. Dr. Lipford	Composition pharmaceutique comprenant un polynucléotide et un antigène notamment pour la vaccination
US6406705B1 (en) *	1997-03-10	2002-06-18	University Of Iowa Research Foundation	Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
CA2289702C (fr) *	1997-05-14	2008-02-19	Inex Pharmaceuticals Corp.	Encapsulation hautement efficace d'agents therapeutiques charges dans des vesicules lipidiques
US6218371B1 (en) *	1998-04-03	2001-04-17	University Of Iowa Research Foundation	Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
AU760795B2 (en) *	1998-05-14	2003-05-22	Coley Pharmaceutical Gmbh	Methods for regulating hematopoiesis using CpG-oligonucleotides
DK1077722T3 (da)	1998-05-22	2006-11-27	Ottawa Health Research Inst	Fremgangsmåder og produkter til induktion af mukosaimmunitet
US20030022854A1 (en)	1998-06-25	2003-01-30	Dow Steven W.	Vaccines using nucleic acid-lipid complexes
US6693086B1 (en) *	1998-06-25	2004-02-17	National Jewish Medical And Research Center	Systemic immune activation method using nucleic acid-lipid complexes
DE60044236D1 (de) *	1999-02-17	2010-06-02	Csl Ltd	Immunogene komplexe und methoden in bezug auf diese
EP1176966B1 (fr) *	1999-04-12	2013-04-03	THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES	Un oligodesoxynucleotide et son emploi pour induire une reponse immunitaire
WO2001022972A2 (fr) *	1999-09-25	2001-04-05	University Of Iowa Research Foundation	Acides nucleiques immunostimulateurs
US6949520B1 (en) *	1999-09-27	2005-09-27	Coley Pharmaceutical Group, Inc.	Methods related to immunostimulatory nucleic acid-induced interferon
US7585847B2 (en)	2000-02-03	2009-09-08	Coley Pharmaceutical Group, Inc.	Immunostimulatory nucleic acids for the treatment of asthma and allergy
US20040131628A1 (en) *	2000-03-08	2004-07-08	Bratzler Robert L.	Nucleic acids for the treatment of disorders associated with microorganisms
US20030129251A1 (en) *	2000-03-10	2003-07-10	Gary Van Nest	Biodegradable immunomodulatory formulations and methods for use thereof
EP1296714B1 (fr) *	2000-06-22	2009-08-26	University Of Iowa Research Foundation	Combinaison de CpG et d'anticorps contre le CD19, CD20, CD22 ou CD40 pour la prévention ou pour le traitement du cancer.
KR100917101B1 (ko) *	2000-08-04	2009-09-15	도요 보세키 가부시키가이샤	플렉시블 금속적층체 및 그 제조방법
EP1366077B1 (fr) *	2000-09-15	2011-05-25	Coley Pharmaceutical GmbH	Procede de criblage a haut rendement d'immuno-agoniste/antagoniste base sur cpg
WO2002069369A2 (fr) *	2000-12-08	2002-09-06	Coley Pharmaceutical Gmbh	Acides nucleiques du type cpg et procedes d'utilisation correspondants
KR100985457B1 (ko) *	2001-06-21	2010-10-06	다이나박스 테크놀로지 코퍼레이션	키메라 면역조절 화합물 및 그것들의 사용 방법
EA007232B1 (ru) *	2001-08-17	2006-08-25	Коли Фармасьютикал Гмбх	Иммуностимулирующие олигонуклеотиды, содержащие комбинацию мотивов и обладающие повышенной активностью
AU2002360278A1 (en) *	2001-10-12	2003-11-11	Coley Pharmaceutical Gmbh	Methods and products for enhancing immune responses using imidazoquinoline compounds
WO2003039595A2 (fr) *	2001-11-07	2003-05-15	Inex Pharmaceuticals Corporation	Modeles ameliores de vaccins administrables par voie muqueuse et modes d'utilisation
US8088388B2 (en) *	2002-02-14	2012-01-03	United Biomedical, Inc.	Stabilized synthetic immunogen delivery system
NZ535952A (en) *	2002-04-04	2009-01-31	Coley Pharm Gmbh	Immunostimulatory G,U-containing oligoribonucleotides
US20040009944A1 (en) *	2002-05-10	2004-01-15	Inex Pharmaceuticals Corporation	Methylated immunostimulatory oligonucleotides and methods of using the same
US7605138B2 (en)	2002-07-03	2009-10-20	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US7576066B2 (en) *	2002-07-03	2009-08-18	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US7569553B2 (en)	2002-07-03	2009-08-04	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en) *	2002-07-03	2004-03-18	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US7807803B2 (en) *	2002-07-03	2010-10-05	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
SG167667A1 (en) *	2002-07-03	2011-01-28	Coley Pharm Group Inc	Nucleic acid compositions for stimulating immune responses
AR040996A1 (es)	2002-08-19	2005-04-27	Coley Pharm Group Inc	Acidos nucleicos inmunoestimuladores
NZ540098A (en) *	2002-10-29	2008-09-26	Coley Pharmaceutical Group Ltd	Use of CPG oligonucleotides in the treatment of hepatitis C virus infection
US7956043B2 (en) *	2002-12-11	2011-06-07	Coley Pharmaceutical Group, Inc.	5′ CpG nucleic acids and methods of use
EP1608403A2 (fr) *	2003-04-02	2005-12-28	Coley Pharmaceutical Group, Ltd.	Formulations de type huile-dans-l'eau a base d'acides nucleiques immunostimulateurs, et procedes d'utilisation associes
KR20060012622A (ko) *	2003-05-16	2006-02-08	하이브리돈, 인코포레이티드	화학요법제와 함께 이뮤노머를 사용하는 상승적 암 치료방법
US7410975B2 (en) *	2003-06-20	2008-08-12	Coley Pharmaceutical Group, Inc.	Small molecule toll-like receptor (TLR) antagonists
US20050013812A1 (en) *	2003-07-14	2005-01-20	Dow Steven W.	Vaccines using pattern recognition receptor-ligand:lipid complexes
JP4989225B2 (ja) *	2003-09-25	2012-08-01	コーリーファーマシューティカルグループ，インコーポレイテッド	核酸親油性接合体
CA2542099A1 (fr) *	2003-10-11	2005-04-21	Inex Pharmaceuticals Corporation	Procedes et compositions permettant de renforcer l'immunite innee et la cytotoxicite cellulaire dependant des anticorps
NZ546275A (en) *	2003-10-30	2009-05-31	Coley Pharm Gmbh	C-class oligonucleotides analogs with enhanced immunostimulatory potency
US20050239733A1 (en) *	2003-10-31	2005-10-27	Coley Pharmaceutical Gmbh	Sequence requirements for inhibitory oligonucleotides
US20050100983A1 (en) *	2003-11-06	2005-05-12	Coley Pharmaceutical Gmbh	Cell-free methods for identifying compounds that affect toll-like receptor 9 (TLR9) signaling
JP2007526253A (ja) *	2004-02-19	2007-09-13	コーリーファーマシューティカルグループ，インコーポレイテッド	免疫刺激性ウイルスｒｎａオリゴヌクレオチド
JP2007531746A (ja) *	2004-04-02	2007-11-08	コーリーファーマシューティカルグループ，インコーポレイテッド	Ｉｌ−１０応答を誘導するための免疫活性化核酸
WO2006080946A2 (fr) *	2004-06-08	2006-08-03	Coley Pharmaceutical Gmbh	Oligonucleotide abasique utilise en tant que plate-forme support pour un antigene ainsi qu'un agoniste et un antagoniste immunostimulatoire
MY159370A (en) *	2004-10-20	2016-12-30	Coley Pharm Group Inc	Semi-soft-class immunostimulatory oligonucleotides
WO2006091915A2 (fr) *	2005-02-24	2006-08-31	Coley Pharmaceutical Group, Inc.	Oligonucleotides immunostimulateurs
EP1874325A2 (fr) *	2005-04-08	2008-01-09	Coley Pharmaceutical Group, Inc.	Methodes de traitement d'un asthme exacerbe par une maladie infectieuse
AU2006241149A1 (en) *	2005-04-26	2006-11-02	Coley Pharmaceutical Gmbh	Modified oligoribonucleotide analogs with enhanced immunostimulatory activity
WO2007008463A2 (fr) *	2005-07-07	2007-01-18	Coley Pharmaceutical Group, Inc.	Polytherapie associant un anticorps anti-ctla-4 et un oligodesoxynucleotide synthetique a motif cpg destinee au traitement du cancer
US20090214578A1 (en) *	2005-09-16	2009-08-27	Coley Pharmaceutical Gmbh	Immunostimulatory Single-Stranded Ribonucleic Acid with Phosphodiester Backbone
KR20080047463A (ko) *	2005-09-16	2008-05-28	콜리 파마슈티칼 게엠베하	뉴클레오티드 변형에 의한 짧은 간섭 리보핵산(ｓｉｒｎａ)의 면역자극 특성의 조절
WO2007062107A2 (fr)	2005-11-25	2007-05-31	Coley Pharmaceutical Gmbh	Oligoribonucleotides immunostimulateurs
EP1986664A4 (fr) *	2006-02-01	2009-07-22	Eyegene Inc	Composition anticancéreuse comprenant un oligonucléotide et des lipopolysaccharides (lps) non toxiques
WO2007095316A2 (fr) *	2006-02-15	2007-08-23	Coley Pharmaceutical Gmbh	Compositions et procédés pour formulations à base d'oligonucléotides
WO2007143582A2 (fr) *	2006-06-05	2007-12-13	Baylor College Of Medicine	Inversion de la fonction supressive de lymphocytes t spécifiques par le signal du récepteur 8 de type toll
MX2009003398A (es)	2006-09-27	2009-08-12	Coley Pharm Gmbh	Analogos de oligonucleotidos cpg que contienen analogos t hidrofobos con actividad inmunoestimuladora mejorada.
US8377898B2 (en) *	2006-10-12	2013-02-19	Idera Pharmaceuticals, Inc.	Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
US20090142362A1 (en) *	2006-11-06	2009-06-04	Avant Immunotherapeutics, Inc.	Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (CETP)
JP2010536907A (ja)	2007-08-31	2010-12-02	ニューリミューンセラピューティクスエイジー	患者にアミロイドーシスおよびタンパク質凝集性障害における特異的免疫応答をもたらす方法
CN101820908A (zh) *	2007-10-09	2010-09-01	科利制药公司	包含改性糖部分的免疫刺激寡核苷酸类似物
WO2009105641A2 (fr) *	2008-02-20	2009-08-27	New York University	Prévention et traitement de dépôt de bêta-amyloïde par stimulation de l'immunité innée
ES2560782T3 (es)	2008-11-04	2016-02-22	Index Pharmaceuticals Ab	Compuestos y métodos para el tratamiento de enfermedades inflamatorias del SNC
BRPI0923225A2 (pt)	2008-12-02	2016-10-04	Chiralgen Ltd	metodo para sintese de acidos nucleicos modificados no atomo de fosforo
KR101856462B1 (ko)	2009-03-25	2018-05-10	보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템	병원체에 대한 포유동물의 선천성 면역 저항성의 자극을 위한 조성물
EP2451461A4 (fr)	2009-07-06	2013-05-29	Ontorii Inc	Nouveaux précurseurs d'acide nucléique et leurs méthodes d'utilisation
JP2013520498A (ja)	2010-02-25	2013-06-06	デュークユニバーシティー	防御的抗ｈｉｖ−１抗体の産生を誘導する方法
NZ729044A (en)	2010-09-09	2020-07-31	Pfizer	4-1bb binding molecules
DK2620428T3 (da)	2010-09-24	2019-07-01	Wave Life Sciences Ltd	Asymmetrisk hjælpegruppe
WO2012084991A1 (fr) *	2010-12-21	2012-06-28	Index Pharmaceuticals Ab	Oligonucléotides biologiquement actifs permettant de moduler le système immun ii
EP2471926A3 (fr)	2010-12-30	2012-07-11	Intervet International BV	Oligodésoxynucléotides immunostimulateurs
CN107365339A (zh)	2011-07-19	2017-11-21	波涛生命科学有限公司	合成官能化核酸的方法
EP2858722B8 (fr)	2012-06-08	2018-02-21	Aduro BioTech, Inc.	Compositions et procédés pour immunothérapie anticancéreuse
AR091569A1 (es)	2012-06-28	2015-02-11	Intervet Int Bv	Receptores de tipo toll
WO2014010250A1 (fr)	2012-07-13	2014-01-16	Chiralgen, Ltd.	Groupe auxiliaire asymétrique
DK2872147T3 (da)	2012-07-13	2023-02-20	Wave Life Sciences Ltd	Fremgangsmåde til fremstilling af kirale oligonukleotider
SG11201500243WA (en) *	2012-07-13	2015-04-29	Shin Nippon Biomedical Lab Ltd	Chiral nucleic acid adjuvant
SG11201502796RA (en)	2012-12-13	2015-05-28	Aduro Biotech Inc	Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
DK3896088T3 (da)	2013-02-20	2025-09-29	Innate Pharma	Behandling af perifert t-cellelymfom
JP2016524593A (ja)	2013-04-29	2016-08-18	メモリアルスローン−ケタリングキャンサーセンター	セカンドメッセンジャーのシグナル伝達を変えるための組成物及び方法
CN105377867B (zh) *	2013-05-03	2019-11-12	加利福尼亚大学董事会	I型干扰素的环状二核苷酸诱导
CU24377B1 (es)	2013-05-18	2018-12-05	Aduro Biotech Inc	Dinucléotidos de purina cíclicos y composiciones de los mismos útiles para inducir la producción de interferón de tipo i dependientes de sting
EP2996472B1 (fr)	2013-05-18	2019-03-27	Aduro Biotech, Inc.	Compositions et procédés d'inhibition de la signalisation dépendante du « stimulateur des gènes interférons »
US20160130346A1 (en)	2013-05-29	2016-05-12	Institut National De La Sante Et De La Recherche Medicale	Kir3dl2 is a biomarker and a therapeutic target useful for respectively preventing and treating a subset of cutaneous and non-cutaneous peripheral t-cell lymphomas
US10176292B2 (en)	2013-07-31	2019-01-08	Memorial Sloan-Kettering Cancer Center	STING crystals and modulators
WO2015048635A1 (fr)	2013-09-27	2015-04-02	Duke University	Liposomes conjugués à mper et leurs utilisations
EP3095459A4 (fr) *	2014-01-15	2017-08-23	Shin Nippon Biomedical Laboratories, Ltd.	Adjuvant d'acide nucléique chiral ayant un effet antitumoral et agent antitumoral
EP3095461A4 (fr) *	2014-01-15	2017-08-23	Shin Nippon Biomedical Laboratories, Ltd.	Adjuvant d'acide nucléique chiral possédant une activité d'induction d'immunité, et activateur d'induction d'immunité
WO2015108046A1 (fr) *	2014-01-15	2015-07-23	株式会社新日本科学	Adjuvant d'acide nucléique chiral ayant une activité anti-allergique, et agent anti-allergique
EP3094728B1 (fr)	2014-01-16	2022-03-09	Wave Life Sciences Ltd.	Conception chirale
AU2015269412B2 (en)	2014-06-04	2020-03-12	Exicure Operating Company	Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
WO2016044839A2 (fr)	2014-09-19	2016-03-24	The Board Of Regents Of The University Of Texas System	Compositions et méthodes pour traiter des infections virales par le biais de l'immunité innée stimulée en combinaison avec des composés antiviraux
WO2016081911A2 (fr)	2014-11-21	2016-05-26	Northwestern University	Absorption cellulaire spécifique à une séquence de conjugués nanoparticulaires d'acides nucléiques sphériques
HUE053145T2 (hu)	2014-12-31	2021-06-28	Checkmate Pharmaceuticals Inc	Kombinált tumor immunterápia
EP3301179B1 (fr) *	2015-07-09	2019-06-05	National Institute for Materials Science	Complexe oligonucléotidique immunostimulant
US11013757B2 (en) *	2016-06-03	2021-05-25	Wave Life Sciences Ltd.	Oligonucleotides, compositions and methods thereof
WO2018039629A2 (fr)	2016-08-25	2018-03-01	Northwestern University	Acides nucléiques sphériques micellaires obtenus à partir de matrices thermosensibles sans trace
US12460208B2 (en)	2017-04-18	2025-11-04	Parr Biotechnology Co., Ltd.	Immunomodulatory polynucleotides and uses thereof
CN108728444A (zh) *	2017-04-18	2018-11-02	长春华普生物技术股份有限公司	免疫调节性多核苷酸及其应用
WO2018209270A1 (fr)	2017-05-11	2018-11-15	Northwestern University	Thérapie cellulaire adoptive utilisant des acides nucléiques sphériques (sna)
CN111511762B (zh)	2017-08-21	2025-05-06	天演药业公司	抗cd137分子及其用途
PL3700564T3 (pl) *	2017-12-15	2026-02-23	Elanco Animal Health Gmbh	Kompozycje immunostymulujące
WO2019148444A1 (fr)	2018-02-02	2019-08-08	Adagene Inc.	Anticorps anti-ctla4 et leurs procédés de fabrication et d'utilisation
WO2019148445A1 (fr)	2018-02-02	2019-08-08	Adagene Inc.	Anticorps activables dépendant de la précision/du contexte, et leurs procédés de fabrication et d'utilisation
WO2019160866A2 (fr)	2018-02-13	2019-08-22	Checkmate Pharmaceuticals, Inc.	Compositions et méthodes d'immunothérapie anti-tumorale
BR112020020479A2 (pt)	2018-04-09	2021-01-12	Checkmate Pharmaceuticals	Empacotamento de oligonucleotídeos em partículas similares a vírus
JP2021521140A (ja) *	2018-04-12	2021-08-26	ウェイブライフサイエンシズリミテッドＷａｖｅＬｉｆｅＳｃｉｅｎｃｅｓＬｔｄ．	オリゴヌクレオチド組成物及びその使用方法
CA3098624A1 (fr)	2018-05-11	2019-11-14	Wave Life Sciences Ltd.	Compositions d'oligonucleotides et leurs procedes d'utilisation
AU2019274654B2 (en)	2018-05-23	2023-07-20	Pfizer Inc.	Antibodies specific for CD3 and uses thereof
US11525010B2 (en)	2018-05-23	2022-12-13	Pfizer Inc.	Antibodies specific for GUCY2c and uses thereof
WO2020128893A1 (fr)	2018-12-21	2020-06-25	Pfizer Inc.	Traitements combinés de cancer comprenant un agoniste de tlr
JP7369297B2 (ja)	2019-12-17	2023-10-25	ファイザー・インク	Ｃｄ４７、ｐｄ－ｌ１に特異的な抗体、およびその使用
US12686870B2 (en)	2020-01-10	2026-07-21	Sbi Biotech Co., Ltd.	TLR9 agonists
EP4149547A4 (fr)	2020-05-13	2024-08-14	Adagene AG	Compositions et méthodes pour le traitement du cancer
WO2022034555A1 (fr) *	2020-08-13	2022-02-17	Janssen Biopharma, Inc.	Constructions polynucléotidiques et leurs utilisations
JP2022161046A (ja) *	2021-04-08	2022-10-21	グラドコフ・アレクセイ	Ｎｋ細胞能力アップ方法

Family Cites Families (157)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4469863A (en)	1980-11-12	1984-09-04	Ts O Paul O P	Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US5023243A (en)	1981-10-23	1991-06-11	Molecular Biosystems, Inc.	Oligonucleotide therapeutic agent and method of making same
EP0092574B1 (fr)	1981-10-23	1992-04-29	Molecular Biosystems, Inc.	Agent therapeutique d'oligonucleotide et ses procedes de fabrication
US4958013A (en)	1989-06-06	1990-09-18	Northwestern University	Cholesteryl modified oligonucleotides
US5399676A (en)	1989-10-23	1995-03-21	Gilead Sciences	Oligonucleotides with inverted polarity
US5177198A (en)	1989-11-30	1993-01-05	University Of N.C. At Chapel Hill	Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
EP0468520A3 (en)	1990-07-27	1992-07-01	Mitsui Toatsu Chemicals, Inc.	Immunostimulatory remedies containing palindromic dna sequences
JPH0874B2 (ja)	1990-07-27	1996-01-10	アイシス・ファーマシューティカルス・インコーポレーテッド	遺伝子発現を検出および変調するヌクレアーゼ耐性、ピリミジン修飾オリゴヌクレオチド
JP3507486B2 (ja)	1991-03-15	2004-03-15	アムジエン・インコーポレーテツド	顆粒球コロニー刺激因子の肺内投与
JPH08502723A (ja)	1992-07-27	1996-03-26	ハイブライドンインコーポレイテッド	オリゴヌクレオチド・アルキルホスホノチオエート
DE4321946A1 (de)	1993-07-01	1995-01-12	Hoechst Ag	Methylphosphonsäureester, Verfahren zu deren Herstellung und deren Verwendung
US6605708B1 (en)	1993-07-28	2003-08-12	Hybridon, Inc.	Building blocks with carbamate internucleoside linkages and oligonucleotides derived therefrom
US5679647A (en)	1993-08-26	1997-10-21	The Regents Of The University Of California	Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5859231A (en)	1993-09-03	1999-01-12	Duke University	Synthesis of oligonucleotides with boranophosphonate linkages
DE4338704A1 (de)	1993-11-12	1995-05-18	Hoechst Ag	Stabilisierte Oligonucleotide und deren Verwendung
US5646126A (en) *	1994-02-28	1997-07-08	Epoch Pharmaceuticals	Sterol modified oligonucleotide duplexes having anticancer activity
US5596091A (en)	1994-03-18	1997-01-21	The Regents Of The University Of California	Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
US6727230B1 (en)	1994-03-25	2004-04-27	Coley Pharmaceutical Group, Inc.	Immune stimulation by phosphorothioate oligonucleotide analogs
WO1995026204A1 (fr) *	1994-03-25	1995-10-05	Isis Pharmaceuticals, Inc.	Stimulation immunitaire par des analogues d'oligonucleotides de phosphorothioate
US5451569A (en)	1994-04-19	1995-09-19	Hong Kong University Of Science And Technology R & D Corporation Limited	Pulmonary drug delivery system
US5658738A (en)	1994-05-31	1997-08-19	Becton Dickinson And Company	Bi-directional oligonucleotides that bind thrombin
US5696248A (en)	1994-06-15	1997-12-09	Hoechst Aktiengesellschaft	3'-modified oligonucleotide derivatives
US6429199B1 (en)	1994-07-15	2002-08-06	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules for activating dendritic cells
US20030026782A1 (en)	1995-02-07	2003-02-06	Arthur M. Krieg	Immunomodulatory oligonucleotides
US6207646B1 (en) *	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US20030050263A1 (en)	1994-07-15	2003-03-13	The University Of Iowa Research Foundation	Methods and products for treating HIV infection
US7935675B1 (en)	1994-07-15	2011-05-03	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US6239116B1 (en)	1994-07-15	2001-05-29	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
AU713040B2 (en)	1994-07-15	1999-11-18	University Of Iowa Research Foundation, The	Immunomodulatory oligonucleotides
DE19502912A1 (de)	1995-01-31	1996-08-01	Hoechst Ag	G-Cap Stabilisierte Oligonucleotide
US5968909A (en)	1995-08-04	1999-10-19	Hybridon, Inc.	Method of modulating gene expression with reduced immunostimulatory response
US6160109A (en)	1995-10-20	2000-12-12	Isis Pharmaceuticals, Inc.	Preparation of phosphorothioate and boranophosphate oligomers
US5856462A (en)	1996-09-10	1999-01-05	Hybridon Incorporated	Oligonucleotides having modified CpG dinucleosides
WO1998016247A1 (fr)	1996-10-11	1998-04-23	The Regents Of The University Of California	Conjugues polynucleotide immunostimulateur/molecule immunomodulatrice
EP0855184A1 (fr)	1997-01-23	1998-07-29	Grayson B. Dr. Lipford	Composition pharmaceutique comprenant un polynucléotide et un antigène notamment pour la vaccination
CA2281838A1 (fr)	1997-02-28	1998-09-03	University Of Iowa Research Foundation	Utilisation d'acides nucleiques contenant des dinucleotides cpg non methyles dans le traitement des troubles associes aux lipopolysaccharides
US6406705B1 (en)	1997-03-10	2002-06-18	University Of Iowa Research Foundation	Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6426334B1 (en)	1997-04-30	2002-07-30	Hybridon, Inc.	Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal
EP1003531B1 (fr)	1997-05-20	2007-08-22	Ottawa Health Research Institute	Procedes de preparation de constructions d'acides nucleiques
US20040006034A1 (en)	1998-06-05	2004-01-08	Eyal Raz	Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
US6589940B1 (en) *	1997-06-06	2003-07-08	Dynavax Technologies Corporation	Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
ATE408422T1 (de)	1997-07-03	2008-10-15	Donald E Macfarlane	Methode zur hemmung immunstimulatorischer mit dna assoziierter antworten
PT1009413E (pt)	1997-09-05	2007-05-31	Univ California	Utilização de oligonucleótidos imumoestimulantes para a prevenção ou tratamento da asma.
JPH11209289A (ja)	1998-01-22	1999-08-03	Taisho Pharmaceut Co Ltd	粘膜免疫誘起剤
US6218371B1 (en)	1998-04-03	2001-04-17	University Of Iowa Research Foundation	Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
CA2326823A1 (fr)	1998-04-20	1999-10-28	Ribozyme Pharmaceuticals, Inc.	Molecules d'acides nucleiques presentant de nouvelles compositions chimiques capables de moduler l'expression genique
EP1077708A1 (fr)	1998-05-06	2001-02-28	University Of Iowa Research Foundation	Methodes de prevention et de traitement des parasitoses et maladies associees a l'aide d'oligonucleotides cpg
AU760795B2 (en)	1998-05-14	2003-05-22	Coley Pharmaceutical Gmbh	Methods for regulating hematopoiesis using CpG-oligonucleotides
DK1077722T3 (da)	1998-05-22	2006-11-27	Ottawa Health Research Inst	Fremgangsmåder og produkter til induktion af mukosaimmunitet
US6562798B1 (en)	1998-06-05	2003-05-13	Dynavax Technologies Corp.	Immunostimulatory oligonucleotides with modified bases and methods of use thereof
US20030022854A1 (en)	1998-06-25	2003-01-30	Dow Steven W.	Vaccines using nucleic acid-lipid complexes
JP2002521489A (ja)	1998-07-27	2002-07-16	ユニバーシティオブアイオワリサーチファウンデーション	ＣｐＧオリゴヌクレオチドの立体異性体および関連する方法
HK1042706A1 (zh)	1998-08-03	2002-08-23	东卡罗来纳大学	低腺苷反义寡核苷酸制剂、组合物、试剂盒及处理
WO2000014217A2 (fr)	1998-09-03	2000-03-16	Coley Pharmaceutical Gmbh	Oligonucleotides a motif g et leurs utilisations
US6207819B1 (en)	1999-02-12	2001-03-27	Isis Pharmaceuticals, Inc.	Compounds, processes and intermediates for synthesis of mixed backbone oligomeric compounds
US6977245B2 (en)	1999-04-12	2005-12-20	The United States Of America As Represented By The Department Of Health And Human Services	Oligodeoxynucleotide and its use to induce an immune response
EP1176966B1 (fr)	1999-04-12	2013-04-03	THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES	Un oligodesoxynucleotide et son emploi pour induire une reponse immunitaire
EP1177439B1 (fr)	1999-04-29	2004-09-08	Coley Pharmaceutical GmbH	Criblage de modificateurs fonctionnels de l'adn immunostimulant
CA2412345A1 (fr)	1999-06-16	2000-12-21	University Of Iowa Research Foundation	Antagonisme des oligonucleotides cpg immunostimulateurs par des 4-aminoquinolines et autres bases faibles
US6514948B1 (en)	1999-07-02	2003-02-04	The Regents Of The University Of California	Method for enhancing an immune response
DE60017259T2 (de)	1999-08-13	2005-12-08	Hybridon, Inc., Cambridge	Modulation der CPG-Oligonukleotid-vermittelten Immunstimulation durch Positionsbedingte Modifikation von Nukleosiden
WO2001022972A2 (fr)	1999-09-25	2001-04-05	University Of Iowa Research Foundation	Acides nucleiques immunostimulateurs
US6949520B1 (en)	1999-09-27	2005-09-27	Coley Pharmaceutical Group, Inc.	Methods related to immunostimulatory nucleic acid-induced interferon
IL148844A0 (en) *	1999-09-27	2002-09-12	Coley Pharm Group Inc	Methods related to immunostimulatory nucleic acid-induced interferon
WO2001051500A1 (fr)	2000-01-14	2001-07-19	The United States Of America, Represented By The Secretary, Department Of Health And Human Services	Oligonucleotide synthetique et son utilisation pour induire une reaction immunitaire
US20010044416A1 (en)	2000-01-20	2001-11-22	Mccluskie Michael J.	Immunostimulatory nucleic acids for inducing a Th2 immune response
WO2001055370A2 (fr)	2000-01-26	2001-08-02	Hybridon, Inc.	MODULATION DE LA STIMULATION IMMUNE INDUITE PAR CpG OLIGONUCLEOTIDIQUE, PAR MODIFICATION DE LA POSITION DES NUCLEOCIDES
US7585847B2 (en)	2000-02-03	2009-09-08	Coley Pharmaceutical Group, Inc.	Immunostimulatory nucleic acids for the treatment of asthma and allergy
US20020156033A1 (en)	2000-03-03	2002-10-24	Bratzler Robert L.	Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer
US20040131628A1 (en)	2000-03-08	2004-07-08	Bratzler Robert L.	Nucleic acids for the treatment of disorders associated with microorganisms
US7129222B2 (en) *	2000-03-10	2006-10-31	Dynavax Technologies Corporation	Immunomodulatory formulations and methods for use thereof
US20030129251A1 (en) *	2000-03-10	2003-07-10	Gary Van Nest	Biodegradable immunomodulatory formulations and methods for use thereof
CA2404041A1 (fr)	2000-03-28	2001-10-04	The Regents Of The University Of California	Procedes concu pour augmenter une reaction de lymphocytes t cytotoxiques in vivo
DE10016079A1 (de) *	2000-03-31	2001-10-04	Alstom Power Nv	Verfahren zum Entfernen von Kohlendioxid aus dem Abgas einer Gasturbinenanlage sowie Vorrichtung zur Durchführung des Verfahrens
HU228264B1 (en)	2000-06-08	2013-02-28	Intercell Ag	Immunostimulatory oligodeoxynucleotides
EP1296714B1 (fr)	2000-06-22	2009-08-26	University Of Iowa Research Foundation	Combinaison de CpG et d'anticorps contre le CD19, CD20, CD22 ou CD40 pour la prévention ou pour le traitement du cancer.
US20020165178A1 (en)	2000-06-28	2002-11-07	Christian Schetter	Immunostimulatory nucleic acids for the treatment of anemia, thrombocytopenia, and neutropenia
US20020198165A1 (en)	2000-08-01	2002-12-26	Bratzler Robert L.	Nucleic acids for the prevention and treatment of gastric ulcers
US20020091097A1 (en)	2000-09-07	2002-07-11	Bratzler Robert L.	Nucleic acids for the prevention and treatment of sexually transmitted diseases
EP1366077B1 (fr)	2000-09-15	2011-05-25	Coley Pharmaceutical GmbH	Procede de criblage a haut rendement d'immuno-agoniste/antagoniste base sur cpg
EP2292632A3 (fr)	2000-09-26	2012-07-25	Idera Pharmaceuticals, Inc.	Modulation de l'activité immunostimulatrice d'analogues oligonucléotidiques immunostimulateurs par des modifications chimiques de position
WO2002069369A2 (fr)	2000-12-08	2002-09-06	Coley Pharmaceutical Gmbh	Acides nucleiques du type cpg et procedes d'utilisation correspondants
AU2002248185A1 (en)	2000-12-14	2002-07-16	Coley Pharmaceutical Group, Inc.	Inhibition of angiogenesis by nucleic acids
US20030050268A1 (en)	2001-03-29	2003-03-13	Krieg Arthur M.	Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
US7176296B2 (en)	2001-04-30	2007-02-13	Idera Pharmaceuticals, Inc.	Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
US7105495B2 (en)	2001-04-30	2006-09-12	Idera Pharmaceuticals, Inc.	Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
US20030129605A1 (en)	2001-05-04	2003-07-10	Dong Yu	Immunostimulatory activity of CpG oligonucleotides containing non-ionic methylphosophonate linkages
US20040132677A1 (en)	2001-06-21	2004-07-08	Fearon Karen L.	Chimeric immunomodulatory compounds and methods of using the same-IV
KR100985457B1 (ko)	2001-06-21	2010-10-06	다이나박스 테크놀로지 코퍼레이션	키메라 면역조절 화합물 및 그것들의 사용 방법
US7666674B2 (en)	2001-07-27	2010-02-23	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
AU2002318944A1 (en)	2001-08-01	2003-02-17	Coley Pharmaceutical Gmbh	Methods and compositions relating to plasmacytoid dendritic cells
AU2002326561B2 (en)	2001-08-07	2008-04-03	Dynavax Technologies Corporation	Immunomodulatory compositions, formulations, and methods for use thereof
US7354909B2 (en)	2001-08-14	2008-04-08	The United States Of America As Represented By Secretary Of The Department Of Health And Human Services	Method for rapid generation of mature dendritic cells
EA007232B1 (ru)	2001-08-17	2006-08-25	Коли Фармасьютикал Гмбх	Иммуностимулирующие олигонуклеотиды, содержащие комбинацию мотивов и обладающие повышенной активностью
AU2002353783A1 (en)	2001-09-24	2003-04-07	The Government Of The United States Of America As Represented By The Secretary Of The Department Of	SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE
WO2003031573A2 (fr)	2001-10-05	2003-04-17	Coley Pharmaceutical Gmbh	Agonistes et antagonistes de signalisation du recepteur 3 de type toll
KR20050048539A (ko) *	2001-10-06	2005-05-24	메리얼엘엘씨	ＣｐＧ 제제 및 관련된 방법
AU2002360278A1 (en)	2001-10-12	2003-11-11	Coley Pharmaceutical Gmbh	Methods and products for enhancing immune responses using imidazoquinoline compounds
WO2003035836A2 (fr)	2001-10-24	2003-05-01	Hybridon Inc.	Modulation des proprietes immunostimulantes de composes a base d'oligonucleotides par presentation optimale d'extremites 5'
US7276489B2 (en)	2002-10-24	2007-10-02	Idera Pharmaceuticals, Inc.	Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
AU2002366710A1 (en) *	2001-12-20	2003-07-09	The Government Of The United States Of America As Represented By The Secretary Of The Department Of	USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
NZ535952A (en)	2002-04-04	2009-01-31	Coley Pharm Gmbh	Immunostimulatory G,U-containing oligoribonucleotides
CN101160399A (zh)	2002-04-22	2008-04-09	拜奥尼茨生命科学公司	寡核苷酸组合物及其在调节免疫应答中的应用
WO2003103586A2 (fr)	2002-06-05	2003-12-18	Coley Pharmaceutical Group, Inc.	Methode de traitement de maladies auto-immunes ou inflammatoires a l'aide de combinaisons d'oligonucleotides inhibiteurs et de petites molecules antagonistes d'acides nucleiques cpg immunostimulateurs
US20040053880A1 (en)	2002-07-03	2004-03-18	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US7605138B2 (en)	2002-07-03	2009-10-20	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US7569553B2 (en)	2002-07-03	2009-08-04	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US7807803B2 (en)	2002-07-03	2010-10-05	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US7576066B2 (en)	2002-07-03	2009-08-18	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
WO2004007743A2 (fr)	2002-07-17	2004-01-22	Coley Pharmaceutical Gmbh	Utilisation d'acides nucleiques cpg dans les maladies a prions
AR040996A1 (es)	2002-08-19	2005-04-27	Coley Pharm Group Inc	Acidos nucleicos inmunoestimuladores
AU2003278845A1 (en)	2002-09-19	2004-04-08	Coley Pharmaceutical Gmbh	Toll-like receptor 9 (tlr9) from various mammalian species
NZ540098A (en)	2002-10-29	2008-09-26	Coley Pharmaceutical Group Ltd	Use of CPG oligonucleotides in the treatment of hepatitis C virus infection
WO2004041183A2 (fr)	2002-11-01	2004-05-21	The Regents Of The University Of California	Procedes de traitement de troubles fibrotiques pulmonaires
US7956043B2 (en)	2002-12-11	2011-06-07	Coley Pharmaceutical Group, Inc.	5′ CpG nucleic acids and methods of use
US7625872B2 (en)	2002-12-23	2009-12-01	Dynavax Technologies Corporation	Branched immunomodulatory compounds and methods of using the same
JP4726630B2 (ja)	2003-01-16	2011-07-20	イデラファーマシューティカルズインコーポレイテッド	修飾された免疫賦活性ジヌクレオチドを用いることによるオリゴヌクレオチドに基づく化合物の免疫賦活特性の調節
EP1608403A2 (fr)	2003-04-02	2005-12-28	Coley Pharmaceutical Group, Ltd.	Formulations de type huile-dans-l'eau a base d'acides nucleiques immunostimulateurs, et procedes d'utilisation associes
WO2004094671A2 (fr)	2003-04-22	2004-11-04	Coley Pharmaceutical Gmbh	Procedes et produits pour identifier et evaluer des ligands des tlr
KR20060012622A (ko)	2003-05-16	2006-02-08	하이브리돈, 인코포레이티드	화학요법제와 함께 이뮤노머를 사용하는 상승적 암 치료방법
US7410975B2 (en)	2003-06-20	2008-08-12	Coley Pharmaceutical Group, Inc.	Small molecule toll-like receptor (TLR) antagonists
MXPA06000619A (es)	2003-07-15	2006-04-11	Hybridon Inc	Estimulacion sinergistica del sistema inmune usando oligonucleotidos inmunoestimuladores y/o compuestos inmunomeros en conjunto con citocinas y/o agentes quimioterapeuticos o terapia de radiacion.
JP4989225B2 (ja)	2003-09-25	2012-08-01	コーリーファーマシューティカルグループ，インコーポレイテッド	核酸親油性接合体
US20050215501A1 (en)	2003-10-24	2005-09-29	Coley Pharmaceutical Group, Inc.	Methods and products for enhancing epitope spreading
NZ546275A (en)	2003-10-30	2009-05-31	Coley Pharm Gmbh	C-class oligonucleotides analogs with enhanced immunostimulatory potency
US20050239733A1 (en)	2003-10-31	2005-10-27	Coley Pharmaceutical Gmbh	Sequence requirements for inhibitory oligonucleotides
US20050100983A1 (en)	2003-11-06	2005-05-12	Coley Pharmaceutical Gmbh	Cell-free methods for identifying compounds that affect toll-like receptor 9 (TLR9) signaling
KR101138131B1 (ko)	2003-12-08	2012-04-23	이데라 파마슈티칼즈, 인코포레이티드	작은 올리고뉴클레오티드-기초 화합물에 의한 면역자극특성의 조절
JP2007526253A (ja)	2004-02-19	2007-09-13	コーリーファーマシューティカルグループ，インコーポレイテッド	免疫刺激性ウイルスｒｎａオリゴヌクレオチド
CA2557443A1 (fr)	2004-03-12	2005-09-29	Hybridon, Inc.	Activite renforcee de vaccin vih utilisant un oligonucleotide immunomodulateur de seconde generation
JP2007531746A (ja)	2004-04-02	2007-11-08	コーリーファーマシューティカルグループ，インコーポレイテッド	Ｉｌ−１０応答を誘導するための免疫活性化核酸
WO2006080946A2 (fr)	2004-06-08	2006-08-03	Coley Pharmaceutical Gmbh	Oligonucleotide abasique utilise en tant que plate-forme support pour un antigene ainsi qu'un agoniste et un antagoniste immunostimulatoire
US7498425B2 (en)	2004-06-15	2009-03-03	Idera Pharmaceuticals, Inc.	Immunostimulatory oligonucleotide multimers
BRPI0512110A (pt)	2004-06-15	2007-10-23	Idera Pharmaceutical Inc	multìmeros de oligonucleotìdeos imunoestimulatórios
US7283209B2 (en) *	2004-07-09	2007-10-16	Carl Zeiss Smt Ag	Illumination system for microlithography
EP1776105A2 (fr)	2004-07-18	2007-04-25	Coley Pharmaceutical Group, Ltd	Methodes et compositions utiles pour induire des reponses immunitaires innees
JP2008506789A (ja)	2004-07-18	2008-03-06	シーエスエル、リミテッド	インターフェロン−ガンマ応答強化を誘発するための免疫刺激複合体及びオリゴヌクレオチド処方物
MY159370A (en)	2004-10-20	2016-12-30	Coley Pharm Group Inc	Semi-soft-class immunostimulatory oligonucleotides
WO2006091915A2 (fr)	2005-02-24	2006-08-31	Coley Pharmaceutical Group, Inc.	Oligonucleotides immunostimulateurs
EP1874325A2 (fr)	2005-04-08	2008-01-09	Coley Pharmaceutical Group, Inc.	Methodes de traitement d'un asthme exacerbe par une maladie infectieuse
AU2006241149A1 (en)	2005-04-26	2006-11-02	Coley Pharmaceutical Gmbh	Modified oligoribonucleotide analogs with enhanced immunostimulatory activity
WO2007008463A2 (fr)	2005-07-07	2007-01-18	Coley Pharmaceutical Group, Inc.	Polytherapie associant un anticorps anti-ctla-4 et un oligodesoxynucleotide synthetique a motif cpg destinee au traitement du cancer
US7490795B2 (en) *	2005-08-31	2009-02-17	Goodrich Corporation	Aircraft evacuation slide with primary gas relief valve
KR20080047463A (ko)	2005-09-16	2008-05-28	콜리 파마슈티칼 게엠베하	뉴클레오티드 변형에 의한 짧은 간섭 리보핵산(ｓｉｒｎａ)의 면역자극 특성의 조절
US20090214578A1 (en)	2005-09-16	2009-08-27	Coley Pharmaceutical Gmbh	Immunostimulatory Single-Stranded Ribonucleic Acid with Phosphodiester Backbone
WO2007038720A2 (fr)	2005-09-27	2007-04-05	Coley Pharmaceutical Gmbh	Modulation de reponses immunitaires mediees par tlr, au moyen d'oligonucleotides d'adaptation
US7776834B2 (en)	2005-11-07	2010-08-17	Idera Pharmaceuticals, Inc.	Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
WO2007062107A2 (fr)	2005-11-25	2007-05-31	Coley Pharmaceutical Gmbh	Oligoribonucleotides immunostimulateurs
WO2007095316A2 (fr)	2006-02-15	2007-08-23	Coley Pharmaceutical Gmbh	Compositions et procédés pour formulations à base d'oligonucléotides
US8027888B2 (en)	2006-08-31	2011-09-27	Experian Interactive Innovation Center, Llc	Online credit card prescreen systems and methods
WO2008033432A2 (fr)	2006-09-12	2008-03-20	Coley Pharmaceutical Group, Inc.	Immunomodulation par des ribonucléosides et des oligoribonucléotides chimiquement modifiés
US20100189772A1 (en)	2006-09-27	2010-07-29	Coley Pharmaceutical Group, Inc	Compositions of TLR ligands and antivirals
MX2009003398A (es)	2006-09-27	2009-08-12	Coley Pharm Gmbh	Analogos de oligonucleotidos cpg que contienen analogos t hidrofobos con actividad inmunoestimuladora mejorada.
EP2104738A2 (fr)	2006-10-26	2009-09-30	Coley Pharmaceuticals GmbH	Oligoribonucleotides et leurs utilisations
US20090142362A1 (en)	2006-11-06	2009-06-04	Avant Immunotherapeutics, Inc.	Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (CETP)
BRPI0811621A2 (pt)	2007-05-17	2014-10-21	Coley Pharm Group Inc	Oligonucleotídeos de classe a com potência imunoestimuladora, composição contendo os mesmos e uso da referida composição
CN101820908A (zh)	2007-10-09	2010-09-01	科利制药公司	包含改性糖部分的免疫刺激寡核苷酸类似物

2003
- 2003-08-15 AR ARP030102974A patent/AR040996A1/es unknown
- 2003-08-18 TW TW092122592A patent/TW200412981A/zh unknown
- 2003-08-18 SV SV2003001602A patent/SV2008001602A/es unknown
- 2003-08-19 HU HUE03788643A patent/HUE030347T2/en unknown
- 2003-08-19 NZ NZ560722A patent/NZ560722A/en not_active IP Right Cessation
- 2003-08-19 ES ES10185869.4T patent/ES2634328T3/es not_active Expired - Lifetime
- 2003-08-19 MX MXPA05002014A patent/MXPA05002014A/es active IP Right Grant
- 2003-08-19 BR BRPI0313414-8A patent/BR0313414A/pt active Search and Examination
- 2003-08-19 US US10/644,052 patent/US8283328B2/en not_active Expired - Fee Related
- 2003-08-19 KR KR1020087001536A patent/KR20080011247A/ko not_active Withdrawn
- 2003-08-19 WO PCT/US2003/025935 patent/WO2004016805A2/fr not_active Ceased
- 2003-08-19 KR KR1020057002841A patent/KR100969727B1/ko not_active Expired - Fee Related
- 2003-08-19 ES ES03788643.9T patent/ES2600553T3/es not_active Expired - Lifetime
- 2003-08-19 PE PE2003000841A patent/PE20040900A1/es not_active Application Discontinuation
- 2003-08-19 PT PT101858694T patent/PT2290078T/pt unknown
- 2003-08-19 PL PL414814A patent/PL232260B1/pl unknown
- 2003-08-19 OA OA1200500045A patent/OA12906A/en unknown
- 2003-08-19 RS YUP-2005/0126A patent/RS20050126A/sr unknown
- 2003-08-19 HU HUE10185869A patent/HUE035336T2/en unknown
- 2003-08-19 UY UY27945A patent/UY27945A1/es not_active Application Discontinuation
- 2003-08-19 DK DK03788643.9T patent/DK1538904T3/en active
- 2003-08-19 AU AU2003259916A patent/AU2003259916B2/en not_active Ceased
- 2003-08-19 NZ NZ538001A patent/NZ538001A/en not_active IP Right Cessation
- 2003-08-19 PL PL375398A patent/PL227938B1/pl unknown
- 2003-08-19 EP EP10185869.4A patent/EP2290078B1/fr not_active Expired - Lifetime
- 2003-08-19 DK DK10185869.4T patent/DK2290078T3/en active
- 2003-08-19 PE PE2008000498A patent/PE20081155A1/es not_active Application Discontinuation
- 2003-08-19 EP EP03788643.9A patent/EP1538904B1/fr not_active Expired - Lifetime
- 2003-08-19 CA CA2493753A patent/CA2493753C/fr not_active Expired - Fee Related
- 2003-08-19 SI SI200332533T patent/SI2290078T1/sl unknown
- 2003-08-19 JP JP2005502069A patent/JP5414961B2/ja not_active Expired - Fee Related
- 2003-08-19 PT PT37886439T patent/PT1538904T/pt unknown
2005
- 2005-01-18 IL IL166376A patent/IL166376A/en active IP Right Grant
- 2005-03-18 NO NO20051469A patent/NO20051469L/no not_active Application Discontinuation
- 2005-03-18 MA MA28164A patent/MA27468A1/fr unknown
- 2005-03-18 EC EC2005005687A patent/ECSP055687A/es unknown
2006
- 2006-10-04 US US11/542,845 patent/US8304396B2/en not_active Expired - Fee Related
2009
- 2009-12-23 AU AU2009251186A patent/AU2009251186B2/en not_active Ceased
2010
- 2010-07-12 JP JP2010158316A patent/JP2011004746A/ja active Pending

Also Published As

Publication number	Publication date
EP2290078A3 (fr)	2013-02-13
EP1538904A2 (fr)	2005-06-15
KR100969727B1 (ko)	2010-07-13
CA2493753C (fr)	2014-07-08
AU2003259916A1 (en)	2004-03-03
DK1538904T3 (en)	2016-11-21
UY27945A1 (es)	2004-03-31
AU2003259916B2 (en)	2010-01-21
PE20081155A1 (es)	2008-08-15
AU2009251186B2 (en)	2013-05-30
OA12906A (en)	2006-10-13
ES2634328T3 (es)	2017-09-27
JP2011004746A (ja)	2011-01-13
TW200412981A (en)	2004-08-01
AU2009251186A1 (en)	2010-01-28
PT2290078T (pt)	2017-07-31
HUE030347T2 (en)	2017-05-29
CA2493753A1 (fr)	2004-02-26
EP2290078B1 (fr)	2017-04-26
US8283328B2 (en)	2012-10-09
KR20080011247A (ko)	2008-01-31
BR0313414A (pt)	2007-07-31
SI2290078T1 (sl)	2017-08-31
AR040996A1 (es)	2005-04-27
DK2290078T3 (en)	2017-07-31
PL375398A1 (en)	2005-11-28
NZ538001A (en)	2008-05-30
WO2004016805A3 (fr)	2005-02-17
WO2004016805A2 (fr)	2004-02-26
PE20040900A1 (es)	2004-12-29
EP1538904B1 (fr)	2016-07-27
JP2006508693A (ja)	2006-03-16
ES2600553T3 (es)	2017-02-09
IL166376A (en)	2012-10-31
PL227938B1 (pl)	2018-01-31
US8304396B2 (en)	2012-11-06
KR20050034738A (ko)	2005-04-14
ECSP055687A (es)	2005-05-30
US20070224210A1 (en)	2007-09-27
EP2290078A2 (fr)	2011-03-02
PL232260B1 (pl)	2019-05-31
MA27468A1 (fr)	2005-08-01
WO2004016805A9 (fr)	2004-08-19
EP1538904A4 (fr)	2008-03-05
JP5414961B2 (ja)	2014-02-12
RS20050126A (sr)	2007-06-04
NZ560722A (en)	2009-10-30
PT1538904T (pt)	2016-11-08
MXPA05002014A (es)	2005-10-19
US20050059619A1 (en)	2005-03-17
SV2008001602A (es)	2008-02-27
IL166376A0 (en)	2006-01-16
PL414814A1 (pl)	2016-03-14
HUE035336T2 (en)	2018-05-02

Legal Events

Date	Code	Title	Description
2013-03-25	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
PL375398A1 (en)	2005-11-28	Immunostimulatory nucleic acids
ATE426412T1 (de)	2009-04-15	Adjuvante influenza-vakzine
WO2004053104A3 (fr)	2005-12-15	Acides nucleiques 5'cpg et leurs methodes d'utilisation
ATE315405T1 (de)	2006-02-15	Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung
MY137619A (en)	2009-02-27	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
WO2004030608A3 (fr)	2005-03-10	Vaccins sous forme de nanoemulsion
DE60335350D1 (de)	2011-01-27	Adjuvantien für dns impstoffe basierend auf imidazochinoline
WO2004098491A3 (fr)	2007-02-22	Procede de prevention d'infections a partir d'agents de terrorisme biologique avec des oligonucleotides cpg immunostimulateurs
ATE292638T1 (de)	2005-04-15	Modulation von oligonukleotid cpg-vermittelter immunstimulation durch modifikation der nucleoside
NO20092023L (no)	2009-06-23	Oligoribonuleotider og anvendelser derav
NO20052426L (no)	2005-05-19	Fremgangsmater for vaksinasjon mot malaria
ATE463575T1 (de)	2010-04-15	Chlamydia antigene, entsprechende dns fragmente und ihre verwendungen
DE60037900D1 (de)	2008-03-13	Chlamydia antigene und entsprechende dna-fragmente und ihre verwendungen
DE60036698D1 (de)	2007-11-22	Chlamydia-antigene und entsprechende dna-fragmente und deren verwendungen
WO2004005476A3 (fr)	2004-05-21	Compositions d'acide nucleique destinees a stimuler les reponses immunitaires
ATE392216T1 (de)	2008-05-15	Mycobakterieller impfstoff
WO2000050073A3 (fr)	2001-02-22	Immunoadjuvant de lps de caulobacter
WO2005081847A3 (fr)	2005-12-22	Reponse immunitaire mucosale puissante induite par des oligonucleotides immunomodulateurs modifies
CY1107845T1 (el)	2013-06-19	Γενετικα εμβολια με ανοσοενισχυτικο
TNSN05052A1 (en)	2007-05-14	Immunostimulatory nucleic acids
SG147465A1 (en)	2008-11-28	Vaccine
AR022758A1 (es)	2002-09-04	Vacunas
BR0207447A (pt)	2004-06-29	Polipeptìdeos e fragmentos de dna correspondentes de streptococcus pyogenes úteis como componentes de vacina
NO20051840L (no)	2005-06-16	IHNV G-protein til immunstimulering.
SG166673A1 (en)	2010-12-29	Immunostimulatory nucleic acids